Skip to main content
SpringerLink
Log in

Cancer in Systemic Sclerosis

  • Chapter
  • First Online:
Scleroderma

  • 2144 Accesses

Abstract

It has long been recognized that patients with systemic sclerosis (scleroderma) have a higher risk of cancer compared to individuals in the general population. This increased risk could be secondary to damage from the disease process itself, a consequence of the immunosuppressive and cytotoxic therapies used to treat scleroderma, common environmental exposures, or from a shared genetic predisposition to develop both cancer and autoimmunity. Alternatively, it has been hypothesized that cancer therapies, including various chemotherapeutic agents and radiation therapy, may trigger the development of vascular and fibrotic complications characteristic of scleroderma. Recent data demonstrate that a subset of patients have paraneoplastic scleroderma due to the development of antitumor immune responses that may become cross-reactive and result in autoimmunity. In this chapter, we explore these potential links between cancer and scleroderma, discuss a paraneoplastic model of scleroderma pathogenesis, and suggest implications for cancer screening and therapeutics in this patient population.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Abu-Shakra M, Guillemin F, Lee P. Cancer in systemic sclerosis. Arthritis Rheum. 1993;36(4):460–4.

    Article  CAS  PubMed  Google Scholar 

  2. Bonifazi M, Tramacere I, Pomponio G, Gabrielli B, Avvedimento EV, La Vecchia C, Negri E, Gabrielli A. Systemic sclerosis (scleroderma) and cancer risk: systematic review and meta-analysis of observational studies. Rheumatology. 2013;52(1):143–54.

    Article  PubMed  Google Scholar 

  3. Derk CT, Rasheed M, Artlett CM, Jimenez SA. A cohort study of cancer incidence in systemic sclerosis. J Rheumatol. 2006;33(6):1113–6.

    PubMed  Google Scholar 

  4. Hill CL, Nguyen AM, Roder D, Roberts-Thomson P. Risk of cancer in patients with scleroderma: a population based cohort study. Annals Rheum Dis. 2003;62(8):728–31.

    Article  CAS  Google Scholar 

  5. Kuo CF, Luo SF, Yu KH, Chou IJ, Tseng WY, Chang HC, Fang YF, Chiou MJ, See LC. Cancer risk among patients with systemic sclerosis: a nationwide population study in Taiwan. Scand J Rheumatol. 2012;41(1):44–9.

    Article  PubMed  Google Scholar 

  6. Olesen AB, Svaerke C, Farkas DK, Sorensen HT. Systemic sclerosis and the risk of cancer: a nationwide population-based cohort study. Br J Dermatol. 2010;163(4):800–6.

    Article  CAS  PubMed  Google Scholar 

  7. Onishi A, Sugiyama D, Kumagai S, Morinobu A. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum. 2013;65(7):1913–21.

    Article  PubMed  Google Scholar 

  8. Rosenthal AK, McLaughlin JK, Gridley G, Nyren O. Incidence of cancer among patients with systemic sclerosis. Cancer. 1995;76(5):910–4.

    Article  CAS  PubMed  Google Scholar 

  9. Siau K, Laversuch CJ, Creamer P, O’Rourke KP. Malignancy in scleroderma patients from south west England: a population-based cohort study. Rheumatol Int. 2011;31(5):641–5.

    Article  PubMed  Google Scholar 

  10. Zhang JQ, Wan YN, Peng WJ, Yan JW, Li BZ, Mei B, Chen B, Yao H, Yang GJ, Tao JH, et al. The risk of cancer development in systemic sclerosis: a meta-analysis. Cancer Epidemiol. 2013;37(5):523–7.

    Article  PubMed  Google Scholar 

  11. Derk CT, Rasheed M, Spiegel JR, Jimenez SA. Increased incidence of carcinoma of the tongue in patients with systemic sclerosis. J Rheumatol. 2005;32(4):637–41.

    PubMed  Google Scholar 

  12. Forbes AM, Woodrow JC, Verbov JL, Graham RM. Carcinoma of breast and scleroderma: four further cases and a literature review. Br J Rheumatol. 1989;28(1):65–9.

    Article  CAS  PubMed  Google Scholar 

  13. Launay D, Le Berre R, Hatron PY, Peyrat JP, Hachulla E, Devulder B, Hebbar M. Association between systemic sclerosis and breast cancer: eight new cases and review of the literature. Clin Rheumatol. 2004;23(6):516–22.

    Article  PubMed  Google Scholar 

  14. Nikpour M, Hissaria P, Byron J, Sahhar J, Micallef M, Paspaliaris W, Roddy J, Nash P, Sturgess A, Proudman S, et al. Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. Arthritis Res Ther. 2011;13(6):R211.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Shah AA, Hummers LK, Casciola-Rosen L, Visvanathan K, Rosen A, Wigley FM. Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated scleroderma. Arthritis Rheumatol. 2015;67(4):1053–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Bobba RK, Holly JS, Loy T, Perry MC. Scar carcinoma of the lung: a historical perspective. Clin Lung Cancer. 2011;12(3):148–54.

    Article  CAS  PubMed  Google Scholar 

  17. Yu YY, Pinsky PF, Caporaso NE, Chatterjee N, Baumgarten M, Langenberg P, Furuno JP, Lan Q, Engels EA. Lung cancer risk following detection of pulmonary scarring by chest radiography in the prostate, lung, colorectal, and ovarian cancer screening trial. Arch Intern Med. 2008;168(21):2326–32; discussion 2332.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Peters-Golden M, Wise RA, Hochberg M, Stevens MB, Wigley FM. Incidence of lung cancer in systemic sclerosis. J Rheumatol. 1985;12(6):1136–9.

    CAS  PubMed  Google Scholar 

  19. Kang KY, Yim HW, Kim IJ, Yoon JU, Ju JH, Kim HY, Park SH. Incidence of cancer among patients with systemic sclerosis in Korea: results from a single centre. Scand J Rheumatol. 2009;38(4):299–303.

    Article  CAS  PubMed  Google Scholar 

  20. Pontifex EK, Hill CL, Roberts-Thomson P. Risk factors for lung cancer in patients with scleroderma: a nested case-control study. Annals Rheum Dis. 2007;66(4):551–3.

    Article  Google Scholar 

  21. Wipff J, Allanore Y, Soussi F, Terris B, Abitbol V, Raymond J, Chaussade S, Kahan A. Prevalence of Barrett’s esophagus in systemic sclerosis. Arthritis Rheum. 2005;52(9):2882–8.

    Article  CAS  PubMed  Google Scholar 

  22. Trivedi PJ, Lammers WJ, van Buuren HR, Pares A, Floreani A, Janssen HL, Invernizzi P, Battezzati PM, Ponsioen CY, Corpechot C, et al. Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut. 2016;65(2):321–9.

    Article  PubMed  Google Scholar 

  23. Cavazza A, Caballeria L, Floreani A, Farinati F, Bruguera M, Caroli D, Pares A. Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers. Hepatology. 2009;50(4):1162–8.

    Article  PubMed  Google Scholar 

  24. Faurschou M, Sorensen IJ, Mellemkjaer L, Loft AG, Thomsen BS, Tvede N, Baslund B. Malignancies in Wegener’s granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol. 2008;35(1):100–5.

    CAS  PubMed  Google Scholar 

  25. Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum. 2010;62(1):9–21.

    Article  CAS  PubMed  Google Scholar 

  26. Brewer JD, Colegio OR, Phillips PK, Roenigk RK, Jacobs MA, Van de Beek D, Dierkhising RA, Kremers WK, McGregor CG, Otley CC. Incidence of and risk factors for skin cancer after heart transplant. Arch Dermatol. 2009;145(12):1391–6.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Marcen R, Galeano C, Fernandez-Rodriguez A, Jimenez-Alvaro S, Teruel JL, Rivera M, Burgos FJ, Quereda C. Effects of the new immunosuppressive agents on the occurrence of malignancies after renal transplantation. Transplant Proc. 2010;42(8):3055–7.

    Article  CAS  PubMed  Google Scholar 

  28. Bichari W, Bartiromo M, Mohey H, Afiani A, Burnot A, Maillard N, Sauron C, Thibaudin D, Mehdi M, Mariat C, et al. Significant risk factors for occurrence of cancer after renal transplantation: a single center cohort study of 1265 cases. Transpl Proc. 2009;41(2):672–3.

    Article  CAS  Google Scholar 

  29. Robson R, Cecka JM, Opelz G, Budde M, Sacks S. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Rranspl: Off J Am Soc Transpl Am Soc Transpl Surg. 2005;5(12):2954–60.

    Article  CAS  Google Scholar 

  30. Berger CC, Bokemeyer C, Schneider M, Kuczyk MA, Schmoll HJ. Secondary Raynaud’s phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer. 1995;31A(13–14):2229–38.

    Article  CAS  PubMed  Google Scholar 

  31. Bessis D, Guillot B, Legouffe E, Guilhou JJ. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol. 2004;51(2 Suppl):S73–6.

    Article  PubMed  Google Scholar 

  32. Clowse ME, Wigley FM. Digital necrosis related to carboplatin and gemcitabine therapy in systemic sclerosis. J Rheumatol. 2003;30(6):1341–3.

    PubMed  Google Scholar 

  33. Cohen IS, Mosher MB, O’Keefe EJ, Klaus SN, De Conti RC. Cutaneous toxicity of bleomycin therapy. Arch Dermatol. 1973;107(4):553–5.

    Article  CAS  PubMed  Google Scholar 

  34. Finch WR, Rodnan GP, Buckingham RB, Prince RK, Winkelstein A. Bleomycin-induced scleroderma. J Rheumatol. 1980;7(5):651–9.

    CAS  PubMed  Google Scholar 

  35. De Angelis R, Bugatti L, Cerioni A, Del Medico P, Filosa G. Diffuse scleroderma occurring after the use of paclitaxel for ovarian cancer. Clin Rheumatol. 2003;22(1):49–52.

    Article  PubMed  Google Scholar 

  36. Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000;43(7):1431–42.

    Article  CAS  PubMed  Google Scholar 

  37. Varga J, Haustein UF, Creech RH, Dwyer JP, Jimenez SA. Exaggerated radiation-induced fibrosis in patients with systemic sclerosis. JAMA. 1991;265(24):3292–5.

    Article  CAS  PubMed  Google Scholar 

  38. Abu-Shakra M, Lee P. Exaggerated fibrosis in patients with systemic sclerosis (scleroderma) following radiation therapy. J Rheumatol. 1993;20(9):1601–3.

    CAS  PubMed  Google Scholar 

  39. Colver GB, Rodger A, Mortimer PS, Savin JA, Neill SM, Hunter JA. Post-irradiation morphoea. Br J Dermatol. 1989;120(6):831–5.

    Article  CAS  PubMed  Google Scholar 

  40. Lacasse Y, Martin S, Gagne D, Lakhal L. Dose-response meta-analysis of silica and lung cancer. Cancer Causes Control: CCC. 2009;20(6):925–33.

    Article  PubMed  Google Scholar 

  41. McCormic ZD, Khuder SS, Aryal BK, Ames AL, Khuder SA. Occupational silica exposure as a risk factor for scleroderma: a meta-analysis. Int Arch Occup Environ Health. 2010;83(7):763–9.

    Article  CAS  PubMed  Google Scholar 

  42. Duncan SC, Winkelmann RK. Cancer and scleroderma. Arch Dermatol. 1979;115(8):950–5.

    Article  CAS  PubMed  Google Scholar 

  43. Lee P, Alderdice C, Wilkinson S, Keystone EC, Urowitz MB, Gladman DD. Malignancy in progressive systemic sclerosis – association with breast carcinoma. J Rheumatol. 1983;10(4):665–6.

    CAS  PubMed  Google Scholar 

  44. Roumm AD, Medsger Jr TA. Cancer and systemic sclerosis. An epidemiologic study. Arthritis Rheum. 1985;28(12):1336–40.

    Article  CAS  PubMed  Google Scholar 

  45. Shah AA, Rosen A, Hummers L, Wigley F, Casciola-Rosen L. Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum. 2010;62(9):2787–95.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Hasegawa M, Sato S, Sakai H, Ohashi T, Takehara K. Systemic sclerosis revealing T-cell lymphoma. Dermatology. 1999;198(1):75–8.

    Article  CAS  PubMed  Google Scholar 

  47. Juarez M, Marshall R, Denton C, Evely R. Paraneoplastic scleroderma secondary to hairy cell leukaemia successfully treated with cladribine. Rheumatology. 2008;47(11):1734–5.

    Article  CAS  PubMed  Google Scholar 

  48. Airo P, Ceribelli A, Cavazzana I, Taraborelli M, Zingarelli S, Franceschini F. Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies. J Rheumatol. 2011;38(7):1329–34.

    Article  CAS  PubMed  Google Scholar 

  49. Moinzadeh P, Fonseca C, Hellmich M, Shah AA, Chighizola C, Denton CP, Ong VH. Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma. Arthritis Res Ther. 2014;16(1):R53.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Shah AA, Casciola-Rosen L, Rosen A. Review: cancer-induced autoimmunity in the rheumatic diseases. Arthritis Rheumatol. 2015;67(2):317–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Kuwana M, Fujii T, Mimori T, Kaburaki J. Enhancement of anti-DNA topoisomerase I autoantibody response after lung cancer in patients with systemic sclerosis. A report of two cases. Arthritis Rheum. 1996;39(4):686–91.

    Article  CAS  PubMed  Google Scholar 

  52. Joseph CG, Darrah E, Shah AA, Skora AD, Casciola-Rosen LA, Wigley FM, Boin F, Fava A, Thoburn C, Kinde I, et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science. 2014;343(6167):152–7.

    Article  CAS  PubMed  Google Scholar 

  53. Casciola-Rosen L, Nagaraju K, Plotz P, Wang K, Levine S, Gabrielson E, Corse A, Rosen A. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med. 2005;201(4):591–601.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Yoshizaki A, Yanaba K, Ogawa A, Asano Y, Kadono T, Sato S. Immunization with DNA topoisomerase I and Freund’s complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling. Arthritis Rheum. 2011;63(11):3575–85.

    Article  CAS  PubMed  Google Scholar 

  55. Bielefeld P. Systemic scleroderma and malignant diseases. A review of the literature. La Rev Med Interne/Fondee Soc Natl Fr Med Interne. 1991;12(5):350–4.

    Article  CAS  Google Scholar 

  56. Fujii T, Mimori T, Kimura N, Satoh S, Hirakata M. Pseudoscleroderma associated with transforming growth factor beta1-producing advanced gastric carcinoma: comment on the article by Varga. Arthritis Rheum. 2003;48(6):1766–7; author reply 1767–8.

    Article  PubMed  Google Scholar 

  57. Querfeld C, Sollberg S, Huerkamp C, Eckes B, Krieg T. Pseudoscleroderma associated with lung cancer: correlation of collagen type I and connective tissue growth factor gene expression. Br J Dermatol. 2000;142(6):1228–33.

    Article  CAS  PubMed  Google Scholar 

  58. Sawaya GF, Kulasingam S, Denberg T, Qaseem A. Cervical cancer screening in average-risk women: best practice advice from the clinical guidelines committee of the American College of Physicians. Annals Intern Med. 2015;162(12):851–9.

    Google Scholar 

  59. Shaheen NJ, Weinberg DS, Denberg TD, Chou R, Qaseem A, Shekelle P, Clinical Guidelines Committee of the American College of P. Upper endoscopy for gastroesophageal reflux disease: best practice advice from the clinical guidelines committee of the American College of Physicians. Annals Intern Med. 2012;157(11):808–16.Pubmed ID-25928075

    Google Scholar 

  60. National Lung Screening Trial Research T, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. New England J Med. 2011;365(5):395–409.

    Article  Google Scholar 

  61. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ, American Association for Study of Liver D. Primary biliary cirrhosis. Hepatology. 2009;50(1):291–308.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, USA

    Ami A. Shah MD, MHS

  2. Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan

    Masataka Kuwana MD, PhD

Authors
  1. Ami A. Shah MD, MHS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masataka Kuwana MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ami A. Shah MD, MHS .

Editor information

Editors and Affiliations

  1. Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA

    John Varga

  2. Division of Medicine, Department of Inflammation, Centre for Rheumatology and Connective Tissue Diseases, UCL Division of Medicine, Royal Free Hospital, London, United Kingdom

    Christopher P. Denton

  3. Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA

    Fredrick M. Wigley

  4. Service de Rhumatologie A, INSERMU1016, Universit. Paris Descartes, Hôpital Cochin, Paris, France

    Yannick Allanore

  5. Department of Allergy and Rheumatology, Nippon Medical School, Graduate School of Medicine, Tokyo, Japan

    Masataka Kuwana

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media New York

About this chapter

Cite this chapter

Shah, A.A., Kuwana, M. (2017). Cancer in Systemic Sclerosis. In: Varga, J., Denton, C., Wigley, F., Allanore, Y., Kuwana, M. (eds) Scleroderma. Springer, Cham. https://doi.org/10.1007/978-3-319-31407-5_37

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-31407-5_37

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-31405-1

  • Online ISBN: 978-3-319-31407-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation